Pfizer Faces $2 Billion Generic Drag On Revenues In 2008

Loss of exclusivity for blockbuster drugs will weigh on Pfizer's top line in the coming year, just as the launch of generic versions of key drugs dragged on the pharma giant's revenues in 2007. Pfizer will face the loss of approximately $2 billion in sales from the loss of Zyrtec and Camptosar in 2008